182 related articles for article (PubMed ID: 33855863)
21. Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: A descriptive time series analysis.
Armstrong-Hough M; Sharma S; Kishore SP; Akiteng AR; Schwartz JI
PLoS One; 2020; 15(12):e0241555. PubMed ID: 33362249
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
23. Country and regional variations in purchase prices for essential cancer medications.
Cuomo RE; Seidman RL; Mackey TK
BMC Cancer; 2017 Aug; 17(1):566. PubMed ID: 28836947
[TBL] [Abstract][Full Text] [Related]
24. Improving access to medicines in poor countries: the role of universities.
Chokshi DA
PLoS Med; 2006 Apr; 3(6):e136. PubMed ID: 16608382
[TBL] [Abstract][Full Text] [Related]
25. Associations between essential medicines and health outcomes for cardiovascular disease.
Steiner L; Fraser S; Maraj D; Persaud N
BMC Cardiovasc Disord; 2021 Mar; 21(1):151. PubMed ID: 33765933
[TBL] [Abstract][Full Text] [Related]
26. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
27. Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
Srivastava D; McGuire A
BMC Public Health; 2014 Jul; 14():767. PubMed ID: 25073407
[TBL] [Abstract][Full Text] [Related]
28. Essential medicines for pediatric oncology in developing countries.
Mehta PS; Wiernikowski JT; Petrilli JA; Barr RD;
Pediatr Blood Cancer; 2013 May; 60(5):889-91. PubMed ID: 23450774
[TBL] [Abstract][Full Text] [Related]
29. Policies and programs to facilitate access to targeted cancer therapies in Thailand.
Sruamsiri R; Ross-Degnan D; Lu CY; Chaiyakunapruk N; Wagner AK
PLoS One; 2015; 10(3):e0119945. PubMed ID: 25798948
[TBL] [Abstract][Full Text] [Related]
30. Pain Treatment Continues To Be Inaccessible for Many Patients Around the Globe: Second Phase of Opioid Price Watch, a Cross-Sectional Study To Monitor the Prices of Opioids.
Pastrana T; Wenk R; Radbruch L; Ahmed E; De Lima L
J Palliat Med; 2017 Apr; 20(4):378-387. PubMed ID: 27923102
[TBL] [Abstract][Full Text] [Related]
31. Ensuring access to essential medicines: some economic considerations.
Maskus KE
Spec Law Dig Health Care Law; 2003 Jul; (291):9-25. PubMed ID: 15206162
[No Abstract] [Full Text] [Related]
32. Availability and affordability of anticancer medicines at the Ocean Road Cancer Institute in Dar es Salaam, Tanzania.
Yohana E; Kamuhabwa A; Mujinja P
East Afr J Public Health; 2011 Mar; 8(1):52-7. PubMed ID: 22066285
[TBL] [Abstract][Full Text] [Related]
33. Innovation and the WHO's essential medicines list: giving credit where credit is due.
Wertheimer AI; Santella TM
Res Social Adm Pharm; 2007 Mar; 3(1):137-44. PubMed ID: 17350562
[No Abstract] [Full Text] [Related]
34. Expansion of cancer care and control in countries of low and middle income: a call to action.
Farmer P; Frenk J; Knaul FM; Shulman LN; Alleyne G; Armstrong L; Atun R; Blayney D; Chen L; Feachem R; Gospodarowicz M; Gralow J; Gupta S; Langer A; Lob-Levyt J; Neal C; Mbewu A; Mired D; Piot P; Reddy KS; Sachs JD; Sarhan M; Seffrin JR
Lancet; 2010 Oct; 376(9747):1186-93. PubMed ID: 20709386
[TBL] [Abstract][Full Text] [Related]
35. Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.
Bird RC
J Law Med Ethics; 2009; 37(2):209-21. PubMed ID: 19493067
[TBL] [Abstract][Full Text] [Related]
36. Selection of oncology medicines in low- and middle-income countries.
Bazargani YT; de Boer A; Schellens JH; Leufkens HG; Mantel-Teeuwisse AK
Ann Oncol; 2014 Jan; 25(1):270-6. PubMed ID: 24356638
[TBL] [Abstract][Full Text] [Related]
37. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
[TBL] [Abstract][Full Text] [Related]
38. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
So AD; Woo J
BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
[TBL] [Abstract][Full Text] [Related]
39. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
40. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
Chivukula MV; Tisocki K
WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
